Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Apr 28, 2023
Q1 2023 quarterly activity and cash flow report
Apr 27, 2023
Appendix 4G
Apr 27, 2023
2022 Annual Report to shareholders
Apr 18, 2023
DAYBUE (trofinetide) launched in US - Neuren earns US$40m
Mar 27, 2023
Application for quotation of securities - NEU
Mar 14, 2023
Investor Presentation, 14 March 2023
Mar 13, 2023
Notification of investor webinar
Mar 13, 2023
FDA approves Daybue - the first treatment for Rett syndrome
Mar 02, 2023
Initial Director's Interest Notice
Mar 02, 2023
Neuren appoints Joe Basile to board of directors
Previous
1
2
3
4
5
Next
